SI-BONE, Inc. — Company profile
Healthcare · Medical Devices · United States
Last price 21.23 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 951.50M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium. The company markets its products primarily with a direct sales force, as well as through third-party sales agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Details
| Name | SI-BONE, Inc. |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 376 |
| Founded | 2008 |
| Ipo Date | 2018-10-17 |
| Ceo | Laura Francis |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US8257041090 |
| Cusip | 825704109 |
| Cik | 0001459839 |
| Sic | 3841 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Laura A. Francis MBA | Chief Executive Officer and Director |
| Jeffrey W. Dunn | Executive Chairman |
| Anshul Maheshwari | Chief Operating Officer and Chief Financial Officer |
| Michael A. Pisetsky J.D. | Chief Business and Legal Affairs Officer, Secretary and General Counsel |
| Anthony J. Recupero | Advisor |
| Dr. Scott A. Yerby Ph.D. | Senior Vice President of Engineering and Chief Technology Officer |
| Ian Bailey | Vice President of Product and Marketing |
| Dr. Daniel Joseph Cher M.D. | Senior Vice President of Clinical, Regulatory Affairs and Quality |
| Dr. W. Carlton Reckling M.D. | Chief Medical Officer and Vice President of Medical Affairs |
| Nikolas F. Kerr | Chief Commercial Officer |
Contact
| Address | 471 El Camino Real, Suite 101, Santa Clara, California 95050, United States |
| Phone | 408 207 0700 |
| Website | https://si-bone.com |